Daré Bioscience, Inc. (DARE): Price and Financial Metrics
GET POWR RATINGS... FREE!
DARE POWR Grades
- Sentiment is the dimension where DARE ranks best; there it ranks ahead of 98.61% of US stocks.
- The strongest trend for DARE is in Growth, which has been heading down over the past 179 days.
- DARE's current lowest rank is in the Momentum metric (where it is better than 4.72% of US stocks).
DARE Stock Summary
- Of note is the ratio of DARE BIOSCIENCE INC's sales and general administrative expense to its total operating expenses; merely 13.91% of US stocks have a lower such ratio.
- The ratio of debt to operating expenses for DARE BIOSCIENCE INC is higher than it is for about only 6.17% of US stocks.
- DARE's price/sales ratio is 8.65; that's higher than the P/S ratio of 87.54% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to DARE BIOSCIENCE INC are DRRX, PULM, INFI, PRQR, and TMBR.
- Visit DARE's SEC page to see the company's official filings. To visit the company's web site, go to www.darebioscience.com.
DARE Valuation Summary
- In comparison to the median Healthcare stock, DARE's price/sales ratio is 76.6% higher, now standing at 8.3.
- Over the past 109 months, DARE's price/sales ratio has gone down 16325.
Below are key valuation metrics over time for DARE.
DARE Growth Metrics
- The 3 year net cashflow from operations growth rate now stands at -185.66%.
- The 4 year price growth rate now stands at -76.67%.
- Its 5 year revenue growth rate is now at -100%.
The table below shows DARE's growth in key financial areas (numbers in millions of US dollars).
|Date||Revenue||Operating Cash Flow||Net Income to Common Stock|
DARE's Quality FactorsThe “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
- DARE has a Quality Grade of D, ranking ahead of 8.05% of graded US stocks.
- DARE's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks.
- WINT, VCEL, and TEVA are the stocks whose asset turnover ratios are most correlated with DARE.
The table below shows DARE's key quality metrics over time.
|Period||Asset Turnover||Gross Margin||ROIC|
DARE Price Target
For more insight on analysts targets of DARE, see our DARE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
|Average Price Target||$5.40||Average Broker Recommendation||1.5 (Moderate Buy)|
DARE Stock Price Chart Interactive Chart >
DARE Price/Volume Stats
|Current price||$1.02||52-week high||$1.88|
|Prev. close||$1.02||52-week low||$0.82|
|Day high||$1.03||Avg. volume||322,211|
|50-day MA||$1.13||Dividend yield||N/A|
|200-day MA||$1.08||Market Cap||86.52M|
Daré Bioscience, Inc. (DARE) Company Bio
DarÃ© Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company intends to develop therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single application that completed Phase 3 clinical trials; Ovaprene, a hormone-free, monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone replacement therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214 injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is based in San Diego, California.
Most Popular Stories View All
DARE Latest News Stream
|Loading, please wait...|
DARE Latest Social Stream
View Full DARE Social Stream
Latest DARE News From Around the Web
Below are the latest news stories about DARE BIOSCIENCE INC that investors may wish to consider to help them evaluate DARE as an investment opportunity.
Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 30, 2023, to review its financial results for the year ended December 31, 2022 and to provide a Company update. To access the conference call via phone, dial (800) 715-9871 (U.S. & Canada) or (646) 307-1963 (international). The conference ID number for the call i
Daré Bioscience to Present at the 35th Annual Roth Conference
SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will present at the 35th Annual Roth Conference, being held March 12-14, 2023 in Laguna Niguel, CA. Ms. Johnson’s presentation is scheduled for Tuesday, March 14th at 8:30 a.m. PDT. A live webcast of the presentation will be available at https://wsw.com/webcast/roth46/dare/1805540 and under “Pres
Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1
SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the start of a Phase 1 study evaluating its development program targeted at treating primary dysmenorrhea by delivering the active pharmaceutical ingredient diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), in a novel way. Daré’s investigational product, DARE-PDM1, will deliver diclofenac vaginally via the Company’s proprietary hydrogel. Primary dysme
Daré Bioscience to Participate in Three February Conferences
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in the following February conferences: 2023 BIO CEO & Investor ConferenceFebruary 6-9, 2023, New York Marriott Marquis, New York, NYCompany presentation: Tuesday, February 7th at 3:00 p.m. ESTMs. Johnson will be available for one-on-one meetings. SVB Securities Global Biopharma Co
Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause
Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication of data from a Phase 1 trial evaluating the pharmacokinetics of DARE-HRT1, an in
DARE Price Returns
Loading social stream, please wait...